Javascript must be enabled to continue!
A Comprehensive Review of Polatuzumab vedotin: Mechanisms, Clinical Applications, and Future Prospects
View through CrossRef
A novel antibody-drug conjugate (ADC), Polatuzumab vedotin has emerged as a promising player in the oncology field. This comprehensive review aims to elucidate the intricate details of Polatuzumab vedotin, encompassing its molecular structure, mechanisms of action, clinical applications, therapeutic efficacy, and ongoing research endeavors. With a focus on precision and targeted therapy, Polatuzumab vedotin stands as a beacon of hope in the battle against various malignancies. It has been regarded as a significant advancement in the field of targeted treatment of diffuse large B-cell lymphoma. As research continues to expand, our understanding of Polatuzumab vedotin, it is evident that its potential to improve patient outcomes and reduce the burden of cancer will remain a topic of great interest for the medical community.
National Board of Examinations
Title: A Comprehensive Review of Polatuzumab vedotin: Mechanisms, Clinical Applications, and Future Prospects
Description:
A novel antibody-drug conjugate (ADC), Polatuzumab vedotin has emerged as a promising player in the oncology field.
This comprehensive review aims to elucidate the intricate details of Polatuzumab vedotin, encompassing its molecular structure, mechanisms of action, clinical applications, therapeutic efficacy, and ongoing research endeavors.
With a focus on precision and targeted therapy, Polatuzumab vedotin stands as a beacon of hope in the battle against various malignancies.
It has been regarded as a significant advancement in the field of targeted treatment of diffuse large B-cell lymphoma.
As research continues to expand, our understanding of Polatuzumab vedotin, it is evident that its potential to improve patient outcomes and reduce the burden of cancer will remain a topic of great interest for the medical community.
Related Results
Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL
Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL
Abstract
Abstract 3699
Background:
A defining feature of HL is CD30 expression by Reed-Sternberg cells. Brentuxim...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
<div>Abstract<p><b>Purpose:</b> The antibody–drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent a...
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
<div>Abstract<p><b>Purpose:</b> The antibody–drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent a...
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study
Abstract
Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults, with an increasing proportion of patients aged ≥ 80 years. Although the POLARIX trial dem...
Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report
Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report
BackgroundThis study reports a case of severe cutaneous toxicity in a patient with metastatic gastric cancer induced by disitamab vedotin, emphasizing the need for careful monitori...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Current and Future Developments in the Treatment of CD30+ Lymphomas
Current and Future Developments in the Treatment of CD30+ Lymphomas
CD30 is a cell membrane protein expressed on the surface of a range of lymphomas, which has important diagnostic, pathogenic, and prognostic roles. The most common CD30+lymphomas a...

